Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK To Buy Reliant

November 26, 2007 | A version of this story appeared in Volume 85, Issue 48

GlaxoSmithKline has agreed to acquire New Jersey-based specialty drug company Reliant Pharmaceuticals for $1.65 billion. Reliant, which had sales of $341 million in the first three quarters of the year, focuses on cardiovascular therapies licensed from other companies. Its key drug is Lovaza, a treatment for patients with very high levels of triglycerides. Lovaza was licensed from Norway's Pronova BioPharma, which will continue to supply the active ingredient, omega-3-acid ethyl esters.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.